

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Assessment of Pentoxifylline effect in reduction of serum C-Reactive Protein (CRP) level in hemodialysis patients in Booali Sina's hemodialysis center

Protocol summary

Summary

Objective: Assessment of Pentoxifylline effect in reduction of serum C-Reactive Protein (CRP) level in hemodialysis patients. Methods: 66 patients entered in this single blind clinical trial. None of them had a inflammatory situation (such as connective tissue Dis., active infections, malignancies, recent traumas, wounds and etc ...) and none of them had taken any anti-inflammatory drugs in 2 months prior to trial. There was no excluding factor of age & sex. They randomly were divided in two groups with 33 patients in each other: One group received 400mg of Pentoxifylline daily (Case group) and another group received placebo (Control Group). Serum CRP level measured at the beginning and end of the trial (after 4 Months) for both groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138901293744N1**

Registration date: **2010-06-20, 1389/03/30**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2010-06-20, 1389/03/30

Registrant information

Name

Arash Kordi

Name of organization / entity

Qazvin University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 28 1333 2930

Email address

akordi@qums.ac.ir

Recruitment status

Recruitment complete

Funding source

Qazvin University of Medical Sciences

Expected recruitment start date

2009-07-23, 1388/05/01

Expected recruitment end date

2009-08-23, 1388/06/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Assessment of Pentoxifylline effect in reduction of serum C-Reactive Protein (CRP) level in hemodialysis patients in Booali Sina's hemodialysis center

Public title

Pentoxifylline effect in reduction of serum C-Reactive Protein (CRP) level in hemodialysis patients

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: hemodialysis patients with ESRD (End Stage Renal Disease) in Booali Sina's hemodialysis center. Exclusion criteria: history of Hypersensitivity to Pentoxifylline, Xanthines (eg, caffeine, theophylline), or any component of the formulation; recent cerebral and/or retinal hemorrhage; inflammatory situations (such as connective tissue Dis., diabetic foot and other vascular problems, active infections, malignancies, recent traumas, wounds and surgeries); and take any

anti-inflammatory drugs in 2 months prior to trial.

Age

No age limit

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: 66

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Single blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethical and research committee of Qazvin University of Medical Sciences

Street address

Shahid Bahonar Blvd.

City

Qazvin

Postal code

Approval date

2009-01-09, 1387/10/20

Ethics committee reference number

2744/20/28

Health conditions studied

1

Description of health condition studied

End Stage Renal Disease

ICD-10 code

N18.0

ICD-10 code description

End Stage Renal Disease

Primary outcomes

1

Description

serum CRP

Timepoint

Before intervention and four months later

Method of measurement

mg/liter with lab-kit(nephelometry)

Secondary outcomes

empty

Intervention groups

1

Description

Pentoxifylline tablet 400 mg/daily for 4 months in intervention group

Category

Treatment - Drugs

2

Description

Placebo tablet /daily for 4 months in control group

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Booali Sina's hospital

Full name of responsible person

Street address

City

Qazvin

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Qazvin University of Medical Sciences

Full name of responsible person

Hossin Sheykhi

Street address

Shahid Bahonar Blvd

City

Qazvin

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Qazvin University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity
Qazvin University of Medical Sciences
Full name of responsible person
Dr. Mahmood Ali Keshavarz
Position
Internal medicine residency
Other areas of specialty/work
Street address
Booali Sina's hospital, Naderi cross
City
Qazvin
Postal code
Phone
+98 28 1333 2930
Fax
+98 28 1332 6033
Email
keshavarz.2008@gmail.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Qazvin University of Medical Sciences
Full name of responsible person
Dr. Arash Kordi
Position
Nephrologist
Other areas of specialty/work
Street address
Qazvin University of Medical Sciences, Shahid
Bahonar Blvd.
City

Qazvin
Postal code
Phone
+98 28 1333 2930
Fax
+98 28 1332 6033
Email
akordy@yahoo.comakordi@qums.ac.ir
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Qazvin University of Medical Sciences
Full name of responsible person
Dr. Mahmood Ali Keshavarz
Position
Internal medicine residency
Other areas of specialty/work
Street address
Booali Sina's hospital, Naderi cross
City
Qazvin
Postal code
Phone
+98 28 1333 2930
Fax
Email
keshavarz.2008@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty